The lateral Trendelenburg position (LTP) may hinder the primary pathophysiologic mechanism of ventilator-associated pneumonia (VAP). We investigated whether placing patients in the LTP would reduce the incidence of VAP in comparison with the semirecumbent position (SRP).
This was a randomized, multicenter, controlled study in invasively ventilated critically ill patients. Two preplanned interim analyses were performed. Patients were randomized to be placed in the LTP or the SRP. The primary outcome, assessed by intention-to-treat analysis, was incidence of microbiologically confirmed VAP. Major secondary outcomes included mortality, duration of mechanical ventilation, and intensive care unit length of stay.
At the second interim analysis, the trial was stopped because of low incidence of VAP, lack of benefit in secondary outcomes, and occurrence of adverse events. A total of 194 patients in the LTP group and 201 in the SRP group were included in the final intention-to-treat analysis. The incidence of microbiologically confirmed VAP was 0.5% (1/194) and 4.0% (8/201) in LTP and SRP patients, respectively (relative risk 0.13, 95% CI 0.02–1.03, p = 0.04). The 28-day mortality was 30.9% (60/194) and 26.4% (53/201) in LTP and SRP patients, respectively (relative risk 1.17, 95% CI 0.86–1.60, p = 0.32). Likewise, no differences were found in other secondary outcomes. Six serious adverse events were described in LTP patients (p = 0.01 vs. SRP).
The LTP slightly decreased the incidence of microbiologically confirmed VAP. Nevertheless, given the early termination of the trial, the low incidence of VAP, and the adverse events associated with the LTP, the study failed to prove any significant benefit. Further clinical investigation is strongly warranted; however, at this time, the LTP cannot be recommended as a VAP preventive measure.
In patients on mechanical ventilation (MV), ventilator-associated pneumonia (VAP) is a common iatrogenic infection , which results in longer periods of MV and additional broad-spectrum antibiotics, ultimately increasing healthcare costs . Although, some reports emphasize a decline in VAP rates over the last decades [3, 4], the overall burden of this iatrogenic condition is still considerable .
In the gastro-pulmonary route of colonization, during MV, the gastrointestinal tract can become colonized by pathogens . Gastrointestinal stress ulcer prophylaxis and enteral nutrition, which alkalinize gastric fluids, were believed to be the main risk for endogenous colonization; yet, recent evidence debates these previous mechanisms . Also, gastroesophageal reflux is consistent in enterally fed patients ; thus, pathogens from the stomach may be aspirated into the airways . Conversely, other investigators have focused on pulmonary aspiration of oropharyngeal pathogens [10, 11], irrespective of gastric colonization.
Several VAP preventive strategies have been developed, which are often applied as a multifaceted bundle . Among those, the semirecumbent position (SRP) has been one of the most implemented measures. The SRP reduces gastroesophageal reflux [8, 13], and a randomized clinical trial demonstrated reduced incidence of VAP, in comparison with the supine fully horizontal position . Later studies reported controversial outcomes , but they were limited by small sample sizes, applied methods, and heterogeneity in the degree of head elevation .
More recently, laboratory studies [17,18,19,20] have shown a drastic reduction in VAP in animals positioned in the Trendelenburg position with a tracheal and endotracheal tube (ETT) orientation below horizontal. In these preclinical studies, the Trendelenburg position limited pulmonary aspiration and improved mucus clearance. Also, in clinical studies [21, 22], reduced risk of respiratory infections was demonstrated in patients in the lateral position, who were turned intermittently from one side to the other. This evidence raised an argument against the rationale of the SRP in the prevention of VAP. Indeed, when the trachea is oriented above horizontal, aspiration of oropharyngeal secretions across the ETT cuff might be facilitated. In humans, the lateral Trendelenburg position (LTP), which is similar to the recovery position, is a feasible option to reproduce the aforementioned interventions.
Theoretically, the LTP could exceed the preventive benefits of the SRP, because pulmonary aspiration, which is the primary mechanism for the development of VAP, would be hindered. In particular, we hypothesized that the LTP would prevent aspiration of bacteria-laden oropharyngeal secretions, and associated pulmonary infections, specifically in critically ill sedated patients, unable to clear respiratory secretions. Therefore, we undertook this translational clinical trial to determine whether the LTP would decrease the incidence of microbiologically confirmed VAP and improve other significant clinical outcomes, in comparison with the SRP.
We conducted a prospective randomized controlled trial in 18 hospitals (Table E1, electronic supplementary material). Patients 18 years old of age or older, expected to be on MV for at least 48 h were assessed for enrollment, within 6 h from endotracheal intubation. Additional detail on inclusion and exclusion criteria is provided in the electronic supplementary material methods. In accordance with local ethical regulations, informed written consents were obtained from the patients or their next of kin. The trial was overseen by an independent data and safety monitoring (DSMB) committee. At the first feasibility/safety interim analysis, the protocol was amended to allow inclusion of patients within 12 h of tracheal intubation. Patients were randomized to be positioned in the LTP, as reported in Fig. 1, or in SRP, with the head of the bed elevated at least 30° (see also electronic supplementary material). Investigators at each institution were blinded to the randomization block length, and laboratory microbiologists were blinded to group assignments. A comprehensive 1-day educational workshop was held before enrollment. In all patients, we used active humidification of respiratory gases. We encouraged study positions until extubation or 14 days of MV, and to not increase sedation to ameliorate compliance. Patients were assessed daily for potential lightening/interruption of sedation, weaning from MV, and compliance with the LTP (Fig. 2). Any change in position and bed angulation was recorded. VAP preventive protocols, implemented prior to the beginning of the trial, were not modified. VAP was clinically suspected in patients with a new pulmonary infiltrate, at least 48 h of MV, and two of the following clinical signs: body temperature greater than 38 °C or less than 35 °C; leukocyte count above 10 × 103 or below 4 × 103 per cubic millimeter; purulent tracheal secretions . In patients who presented pulmonary infiltrates upon randomization, only new pulmonary infiltrates, developing after 48 h of MV were considered pathognomonic of VAP. Study primary outcome was incidence of VAP (within the first 14 days), confirmed by quantitative bronchoalveolar lavage (BAL) or mini-BAL cultures at least 104 colony-forming units (cfu)/ml. Secondary and tertiary outcomes included intensive care unit (ICU) and hospital stays; duration of MV; all-cause mortality at 28 days, in the ICU and hospital; use of sedatives, analgesics, and antibiotics. We computed daily defined dose of antibiotics (DDD) , lorazepam and morphine equivalents , and propofol dosage. Any adverse (AE) and serious adverse event (SAE) was recorded. Finally, nurses’ feasibility and workload were assessed. After inclusion of 137 patients, the DSMB recommended additional neurological evaluation (see methods in the electronic supplementary material).
Full description of statistical analyses is provided in the electronic supplementary material. We calculated that 400 patients for each group should have been enrolled to detect a reduction in primary outcome from 15.0% to 7.5%, for a statistical power of 90%, with a two-sided alpha significance level of 0.05. We conducted an intention-to-treat analysis, on the basis of the preplanned statistical analysis plan and in accordance with the CONSORT statement . Fisher’s exact test and Wilcoxon rank-sum tests were used to analyze categorical and continuous variables, respectively. We estimated the measure of effect of the intervention by calculating unadjusted relative risk (RR) and its 95% confidence interval (CI). Also, we used competing risk analysis  to assess the effect of body positions on VAP incidence. We estimated the effect of the intervention using cause-specific hazard ratios (HR), through the Cox proportional hazards model. As for continuous secondary outcomes, risk differences were estimated by the median of all paired differences between groups and their 95% CI (Hodges–Lehmann method) . We used the log-rank test to compare Kaplan–Meier curves of 28-day survival and we estimated the 28-day HR using a Cox proportional hazards model. We used complier average causal effect (CACE) analyses to estimate effect of the interventions, while accounting for protocol adherence and respecting the intention-to-treat principle . Finally, after a comprehensive evaluation of the findings of aforementioned analyses, the steering committee agreed to perform a single post hoc analysis, clustering the patients on the basis of the presence or absence of pulmonary infiltrates at baseline. The rationale for this analysis was based on the well-recognized challenges in the diagnosis of VAP, through standard clinical variables and chest radiographs. Indeed, a new pulmonary infiltrate could be difficult to detect in patients with an abnormal chest radiograph at baseline. Post hoc analyses were conducted through the Mantel–Haenszel test for homogeneity for binary outcomes and by modelling a negative-binomial regression model for duration of MV and ICU or hospital stay. All tests were two sided, and there was no adjustment for multiplicity. A p value of 0.05 was considered as statistically significant. Stata 13.1 was used for all analyses.
Between December 2, 2010 and April 20, 2015, we screened 2156 patients in 18 ICUs (Fig. E1 and Table E1, electronic supplementary material). Of these patients, 401 were enrolled; of whom, five later withdrew from the study. One patient in the semirecumbent group was erroneously included twice; thus, only the first randomization was included. This resulted in an intention-to-treat population of 395 patients (194 in the lateral Trendelenburg group and 201 in the semirecumbent group) (Fig. 3). Baseline characteristics of the patients are reported in Table 1.
Recruitment was stopped in May 2015, at the second interim analysis. The DSMB reviewed the results of 395 patients and recommended to stop the study for low incidence of VAP in the control group, lack of benefits in any major secondary outcome, and adverse events in the LTP group (see electronic supplementary material). The trial steering committee adopted the DSMB advice and stopped the trial.
Overall, 23 (11.9%) and 7 (3.5%) of the patients, in LTP and SRP, respectively, were never managed in the randomized position (p < 0.01). The median time to the first positioning was delayed in the LTP, in comparison with the SRP, 3 (IQR 1–7) and 0.3 (IQR 0–2) h, respectively (p < 0.01). Patients in the LTP were appropriately positioned for a 32.7% (median) of the study time (IQR 15.4–57.8%); whereas, patients in the SRP were correctly positioned for 93.6% (IQR 89.0–96.3%) of the time. In hospital with a primary focus on research, patients in the LTP were appropriately positioned for 30.4% of the study time (IQR 15.4–54.1%); whereas, patients in general hospitals were appropriately positioned for 35.9% (IQR 16.1–63.0%, p = 0.51). Crossover never occurred in the SRP group; conversely, it occurred in 160 LTP patients (93.6%). Reasons for changing from the LTP to SRP are depicted in Fig. E2. In compliance with the protocol depicted in Fig. 2, crossover increased after a few days of MV. Indeed, as reported in Fig. E3-A in the electronic supplementary material, median fraction of time in LTP reached 51.8% (IQR 20.7–79.2) during the first 2 days, then progressively decreased, as sedation was lightened (Fig. E3-B). Overall, bed angulation in the LTP was −5.6° ± 2° and 34.1° ± 6° in the SRP position (p < 0.01).
The incidence of microbiologically confirmed VAP was 0.5% (1/194 patients) in patients positioned in LTP, and 4.0% (8/201 patients) in patients in SRP (relative risk 0.13, 95% CI 0.02–1.03; risk difference −3.5%, 95% CI −6.4 to −0.6; p = 0.04) (Table 2). Among all patients with clinical suspicion of VAP, 32 underwent distal pulmonary sampling; in particular, 18/21 (85.7%) of the SRP patients and 14/18 (77.8%) of the LTP patients (p = 0.68). Antibiotics were inappropriately changed, before distal sampling, in three patients of each group (p = 0.77). Overall, 26 BALs and six mini-BALs were performed. The cumulative probability of VAP was lower in the LTP than in the SRP group (Fig. 4a), cause-specific HR was 0.13 (95% CI 0.02–1.00, p = 0.05) (Table E2). The most common VAP causative pathogens in BAL fluids were Staphylococcus aureus and Klebsiella pneumonia (Table E3).
We did not find any between-group difference in ICU or hospital mortality rates and length of stay on MV (Table 2; Fig. 4b). Multiple organ failure was the most common cause of death in ICU, without difference between groups (Table E4). Table E5 depicts CACE analysis of primary and secondary outcomes. Importantly, a risk difference of −7.6% (95% CI −14 to −1.1%, p = 0.02) in microbiologically confirmed VAP was found in favor of the LTP. In the CACE analysis, we did not find any significant difference in mortality rates.
Frequency of bacteremia or other potential infections did not differ between groups (Table E6). There were no statistically significant differences between groups in the duration of treatment, nor total doses of sedatives or opioids (Table E7). Likewise, median consumption of antibiotics was similar, 10.2 (IQR 2–23.1) and 8 DDDs (IQR 2–22) in the LTP and SRP group (p = 0.53) (Table E8). We did not find any difference in the use of enteral or parental nutrition and calorie intake (Table E9). Nurses reported greater difficulties in positioning the patient in LTP and higher workload (Table E10). However, approximately 50% of the patients were easily or very easily positioned in LTP. Finally, these challenges slightly ameliorated through practice, as more patients were enrolled (Fig. E4).
Rate of AEs was comparable among the two groups, except for vomiting that was more frequent in LTP (8.3% vs 2.5% in SRP, p = 0.01) (Table 3). Among patients who were placed in the randomized positions, no SAEs were reported in the SRP; whilst, six SAEs were described in LTP patients (0/194 vs. 6/171, respectively, p = 0.01), of whom four had pre-existing liver diseases (Table 3). Among these events, four were definitely related to the LTP—mainly transient oxygen desaturation and hemodynamic instability—while two events (intracranial hemorrhage and brachial plexus injury) were possibly related. Neurological evaluation, upon discharge from the ICU, was comparable between groups (Table E11).
Post hoc analysis
Post hoc interaction exploratory analyses showed that incidence of clinically suspected VAP was lower in LTP patients without pulmonary infiltrates at the time of enrollment, in comparison with SRP, but higher in patients with pulmonary infiltrates (Table E12) (RR with pulmonary infiltrates 1.69, 95% CI 0.71–4.04; RR without pulmonary infiltrates 0.42, CI 0.12–1.23, p = 0.04 for interaction).
In our study, the incidence of microbiologically confirmed VAP was lower in LTP, in comparison with the SRP. Yet, the DSMB suggested early trial termination because of low incidence of VAP, lack of benefits in secondary outcomes, and serious adverse events in LTP patients. Therefore, as a result of the aforementioned limitations and inconclusiveness of the findings, the LTP cannot be recommended as a VAP preventive measure until further investigation is available.
In our analysis, we primarily focused on the first 2 weeks of MV. Previous studies [30,31,32] have consistently corroborated that patients are at higher risk of VAP during this period. Additionally, as reported in Table 2, the median duration of MV was approximately 5 days, highlighting the importance of close monitoring and preventive measures during the first week. We did find, in LTP patients, a decrease in VAP, but as a result of the very low incidence, the results are questionable. Such low incidence is in line with other previous trials , and might be related to the consistent decline in VAP rates reported in the last decade [3, 4]. Also, all local infection control measures were not modified, and possibly efficiently implemented. Nonetheless, it is important to emphasize that in our population the median time on MV was 4–5 days. In this context, the incidence density of microbiologically confirmed VAP, in the SRP and LTP groups, was 7.19 and 0.12 per 1000 ventilator days, respectively (p = 0.02). Thus, the incidence density in the SRP was comparable to the rates reported in other studies from developed countries . We found comparable clinically suspected episodes of VAP between groups. This could be related to higher risks of atelectasis in LTP, which potentially encouraged physicians to perform BALs in patients with unspecific clinical signs of respiratory infections.
As reported in Table 2, mortality in the LTP was higher than in the SRP group, although the difference was not statistically significant. Our study was specifically aimed at evaluating feasibility and efficacy of the novel intervention, and it was likely underpowered to detect differences in mortality. Yet, these data call for a comprehensive assessment of the safety of the intervention, particularly considering the apparent risk of mortality in patients with pulmonary infiltrates upon intubation (Table E12). Also, SAEs were reported in LTP patients, mainly brief episodes of respiratory and hemodynamic instability, which often occur during routine patient mobilization, specifically in patients who presented ascites. Yet, these differences in SAEs between groups are troubling and suggest potential safety issues. Finally, a slight trend toward higher risk of other infections was reported in LTP patients (Table E6). Potential reasons for lack of benefits on mortality, higher risk of SAEs, and development of infections are difficult to discern and, at this time, can only be speculative. For instance, LTP patients were mobilized more frequently and contralateral propagation of noxious biofluids could have been promoted . Also, frequent manipulation of artificial airways and indwelling devices could have increased risks of nosocomial infections. Nevertheless, on the basis of the results from animal studies [17,18,19], LTP patients could have also benefited from the increased clearance of pulmonary biofluids. It should also be considered that in LTP patients, with severe lung injury, ventilatory management might have been challenging. Indeed, we could speculate that in LTP abdominal contents were pushed upward against the diaphragm and pulmonary atelectasis could have developed, increasing risks of lung injury. We did not observe augmented neurological risks in LTP; yet, it would also be advisable to further explore short- and long-term neurological effects. Finally, higher rates of vomiting did not increase the risk of VAP in LTP, confirming prevention of gastro-pulmonary aspiration.
As for the compliance to the novel intervention, the study was designed to promote LTP, specifically in patients requiring higher level of sedation—i.e., during first hours of MV and with higher severity of critical illness—and at higher risk of pulmonary aspiration. Therefore, the highest compliance was achieved in deeply sedated patients, during the first days of MV (Fig. E3). Then, as expected, compliance decreased when the patient progressed through the weaning period. As a result, crossover from the LTP to SRP occurred in more than 90% of the patients; whereas, SRP patients were maintained in the same position, throughout the study time. Of note, hemodynamic and respiratory instability was the reason for changing from LTP to SRP in more than 30% of the cases (Fig. E2). This indicates potential safety risks that should be further explored to identify populations at risk. At times, the nurses encountered difficulties executing the LTP and a few factors should be considered when interpreting these findings. First, patients in the SRP are mobilized less, causing better acceptance of the intervention. Indeed, recommended lateral rotation every 2–4 h is seldom implemented , and patients are repositioned only when they slide down the bed . Second, in the SRP surgical drains, tubes, and vascular lines can be easily accessed. Finally, in ICU settings concomitant procedures and understaffed nursing shifts limit applicability of rigid schedules for patient positioning.
In comparison with previous randomized trials on body position , this work presents several strengths. First, this is the largest clinical trial that evaluated the effects of body positions in the prevention of VAP. Second, we used invasive methods to increase specificity of VAP diagnosis. Indeed, we expected that LTP amplified gravity-driven clearance of mucus and risks of tracheal colonization. Therefore, culture of endotracheal aspirates would have overestimated VAP incidence. Third, according to the latest statistical standards in this field , we used competing risk analysis to adjust for duration of MV and death. Fourth, data were analyzed according to the intention-to-treat principle and CACE analysis, and the robustness of this latter analysis should be noted . Indeed, in randomized trials testing new interventions, non-adherence could occur in a nonrandom fashion and differ among groups. In this case, the traditional “per-protocol” approach would generate biased results. Conversely, CACE analysis account for adherence, while preserving the intention-to-treat principle, and generates more accurate estimations of efficacy and safety.
Yet, our study has various limitations. Only microbiologists, assessing the primary outcome, were blinded to group assignments, because blinding the attending physician was impossible. Second, as reported in Fig. 3, approximately 60% of the screened patients met exclusion criteria. This could have caused selection bias and reduced generalizability of our findings. Nevertheless, several exclusion criteria were specifically listed to ensure patient safety. Third, continuous computerized monitoring of body position was not employed ; hence, changes in position might have been underreported. Fourth, VAP cases were not subject to central, independent adjudication, by a committee blinded to the study group. This rigorous adjudication would have likely strengthened the reliability of the diagnostic process. Yet, we used strict microbiological methods to ultimately diagnose VAP. Fifth, as it could be inferred by Table 2, we enrolled a population specifically at risk of early-onset VAP. Thus, the LTP might have promoted clearance of pathogens aspirated at intubation, or early thereafter. However, the effects of the LTP on VAP prevention cannot be straightforwardly extrapolated to the population at risk of late-onset VAP. Sixth, assessment of neurological complications upon discharge was suboptimal and only initiated after DSMB recommendation. Also, we did not closely monitor agitation/delirium; therefore, a comprehensive evaluation of neurological effects of LTP should be undertaken in future studies. Finally, premature termination of our trial has limited inferences regarding VAP preventive efficacy.
In a population at low risk of VAP, LTP caused a reduction in microbiologically confirmed VAP, but the results are inconclusive because of the lack of other clinical benefits, increased safety risks, and challenges in nursing compliance. Given the limitations of our study, potential future clinical studies should carefully re-examine the targeted population, VAP diagnostic methods, outcomes, and incidence of nosocomial infections among collaborating centers. Finally, considering that in our study the LTP was commonly applied during the first days of MV, prolonged use of such a position seems futile and at risk of adverse events.
Wang Y, Eldridge N, Metersky ML, Verzier NR, Meehan TP, Pandolfi MM, Foody JM, Ho SY, Galusha D, Kliman RE, Sonnenfeld N, Krumholz HM, Battles J (2014) National trends in patient safety for four common conditions, 2005-2011. N Engl J Med 370:341–351. doi:10.1056/NEJMsa1300991
Warren DK, Shukla SJ, Olsen MA, Kollef MH, Hollenbeak CS, Cox MJ, Cohen MM, Fraser VJ (2003) Outcome and attributable cost of ventilator-associated pneumonia among intensive care unit patients in a suburban medical center. Crit Care Med 31:1312–1317. doi:10.1097/01.CCM.0000063087.93157.06
Metersky ML, Wang Y, Klompas M, Eckenrode S, Bakullari A, Eldridge N (2016) Trend in ventilator-associated pneumonia rates between 2005 and 2013. JAMA 316:2427–2429. doi:10.1001/jama.2016.16226
Dudeck MA, Edwards JR, Allen-Bridson K, Gross C, Malpiedi PJ, Peterson KD, Pollock DA, Weiner LM, Sievert DM (2015) National Healthcare Safety Network (NHSN) report, data summary for 2013, device-associated module. Am J Infect Control 43:206–221. doi:10.1016/j.ajic.2014.11.014
Rosenthal VD, Al-Abdely HM, El-Kholy AA, AlKhawaja SA, Leblebicioglu H, Mehta Y, Rai V, Hung NV, Kanj SS, Salama MF, Salgado-Yepez E, Elahi N, Morfin Otero R, Apisarnthanarak A, De Carvalho BM, Ider BE, Fisher D, Buenaflor MC, Petrov MM, Quesada-Mora AM, Zand F, Gurskis V, Anguseva T, Ikram A, Aguilar de Moros D, Duszynska W, Mejia N, Horhat FG, Belskiy V, Mioljevic V, Di Silvestre G, Furova K, Ramos-Ortiz GY, Gamar Elanbya MO, Satari HI, Gupta U, Dendane T, Raka L, Guanche-Garcell H, Hu B, Padgett D, Jayatilleke K, Ben Jaballah N, Apostolopoulou E, Prudencio Leon WE, Sepulveda-Chavez A, Telechea HM, Trotter A, Alvarez-Moreno C, Kushner-Davalos L (2016) International Nosocomial Infection Control Consortium report, data summary of 50 countries for 2010-2015: device-associated module. Am J Infect Control 44:1495–1504. doi:10.1016/j.ajic.2016.08.007
Torres A, El-Ebiary M, Soler N, Montón C, Fàbregas N, Hernández C (1996) Stomach as a source of colonization of the respiratory tract during mechanical ventilation: association with ventilator-associated pneumonia. Eur Respir J 9:1729–1735
Krag M, Perner A, Wetterslev J, Wise MP, Hylander Møller M (2014) Stress ulcer prophylaxis versus placebo or no prophylaxis in critically ill patients. A systematic review of randomised clinical trials with meta-analysis and trial sequential analysis. Intensive Care Med 40:11–22
Torres A, Serra-Batlles J, Ros E, Piera C, Puig de la Bellacasa J, Cobos A, Lomeña F, Rodríguez-Roisin R (1992) Pulmonary aspiration of gastric contents in patients receiving mechanical ventilation: the effect of body position. Ann Intern Med 116:540–543
Torres A, el-Ebiary M, González J, Ferrer M, Puig de la Bellacasa J, Gené A, Martos A, Rodriguez-Roisin R (1993) Gastric and pharyngeal flora in nosocomial pneumonia acquired during mechanical ventilation. Am Rev Respir Dis 148:352–357
Nseir S, Zerimech F, Fournier C, Lubret R, Ramon P, Durocher A, Balduyck M (2011) Continuous control of tracheal cuff pressure and microaspiration of gastric contents in critically ill patients. Am J Respir Crit Care Med 184:1041–1047. doi:10.1164/rccm.201104-0630OC
Philippart F, Gaudry S, Quinquis L, Lau N, Ouanes I, Touati S, Nguyen JC, Branger C, Faibis F, Mastouri M, Forceville X, Abroug F, Ricard JD, Grabar S, Misset B, TOP-Cuff Study Group (2015) Randomized intubation with polyurethane or conical cuffs to prevent pneumonia in ventilated patients. Am J Respir Crit Care Med 191:637–645. doi:10.1164/rccm.201408-1398OC
Branch-Elliman W, Wright SB, Howell MD (2015) Determining the ideal strategy for ventilator-associated pneumonia prevention: cost-benefit analysis. Am J Respir Crit Care Med 192:57–63. doi:10.1164/rccm.201412-2316OC
Orozco-Levi M, Torres A, Ferrer M, Piera C, el-Ebiary M, de la Bellacasa JP, Rodriguez-Roisin R (1995) Semirecumbent position protects from pulmonary aspiration but not completely from gastroesophageal reflux in mechanically ventilated patients. Am J Respir Crit Care Med 152:1387–1390
Drakulovic MB, Torres A, Bauer TT, Nicolas JM, Nogué S, Ferrer M (1999) Supine body position as a risk factor for nosocomial pneumonia in mechanically ventilated patients: a randomised trial. Lancet 354:1851–1858. doi:10.1016/S0140-6736(98)12251-1
Wang L, Li X, Yang Z, Tang X, Yuan Q, Deng L, Sun X (2016) Semi-recumbent position versus supine position for the prevention of ventilator-associated pneumonia in adults requiring mechanical ventilation. Cochrane Database Syst Rev. doi:10.1002/14651858.CD009946.pub2
van Nieuwenhoven CA, Vandenbroucke-Grauls C, van Tiel FH, Joore HC, van Schijndel RJ, van der Tweel I, Ramsay G, Bonten MJ (2006) Feasibility and effects of the semirecumbent position to prevent ventilator-associated pneumonia: a randomized study. Crit Care Med 34:396–402. doi:10.1097/01.CCM.0000198529.76602.5E
Li Bassi G, Marti JD, Saucedo L, Rigol M, Roca I, Cabanas M, Muñoz L, Ranzani OT, Giunta V, Luque N, Esperatti M, Gabarrus A, Fernandez L, Rinaudo M, Ferrer M, Ramirez J, Vila J, Torres A (2014) Gravity predominates over ventilatory pattern in the prevention of ventilator-associated pneumonia. Crit Care Med 42:e620–e627. doi:10.1097/CCM.0000000000000487
Li Bassi G, Zanella A, Cressoni M, Stylianou M, Kolobow T (2008) Following tracheal intubation, mucus flow is reversed in the semirecumbent position: possible role in the pathogenesis of ventilator-associated pneumonia. Crit Care Med 36:518–525. doi:10.1097/01.CCM.0000299741.32078.E9
Panigada M, Berra L, Greco G, Stylianou M, Kolobow T (2003) Bacterial colonization of the respiratory tract following tracheal intubation-effect of gravity: an experimental study. Crit Care Med 31:729–737. doi:10.1097/01.CCM.0000049943.01252.E5
Zanella A, Cressoni M, Epp M, Hoffmann V, Stylianou M, Kolobow T (2012) Effects of tracheal orientation on development of ventilator-associated pneumonia: an experimental study. Intensive Care Med 38:677–685. doi:10.1007/s00134-012-2495-2
Mauri T, Berra L, Kumwilaisak K, Pivi S, Ufberg JW, Kueppers F, Pesenti A, Bigatello LM (2010) Lateral-horizontal patient position and horizontal orientation of the endotracheal tube to prevent aspiration in adult surgical intensive care unit patients: a feasibility study. Respir Care 55:294–302
Aly H, Badawy M, El-Kholy A, Nabil R, Mohamed A (2008) Randomized, controlled trial on tracheal colonization of ventilated infants: can gravity prevent ventilator-associated pneumonia? Pediatrics 122:770–774. doi:10.1542/peds.2007-1826
Kalil AC, Metersky ML, Klompas M, Muscedere J, Sweeney DA, Palmer LB, Napolitano LM, O’Grady NP, Bartlett JG, Carratalà J, El Solh AA, Ewig S, Fey PD, File TM Jr, Restrepo MI, Roberts JA, Waterer GW, Cruse P, Knight SL, Brozek JL (2016) Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clin Infect Dis 63:e61–e111. doi:10.1093/cid/ciw353
de Jong E, van Oers JA, Beishuizen A, Vos P, Vermeijden WJ, Haas LE, Loef BG, Dormans T, van Melsen GC, Kluiters YC, Kemperman H, van den Elsen MJ, Schouten JA, Streefkerk JO, Krabbe HG, Kieft H, Kluge GH, van Dam VC, van Pelt J, Bormans L, Otten MB, Reidinga AC, Endeman H, Twisk JW, van de Garde EM, de Smet AM, Kesecioglu J, Girbes AR, Nijsten MW, de Lange DW (2016) Efficacy and safety of procalcitonin guidance in reducing the duration of antibiotic treatment in critically ill patients: a randomised, controlled, open-label trial. Lancet Infect Dis 16:819–827. doi:10.1016/S1473-3099(16)00053-0
Schweickert WD, Gehlbach BK, Pohlman AS, Hall JB, Kress JP (2004) Daily interruption of sedative infusions and complications of critical illness in mechanically ventilated patients. Crit Care Med 32:1272–1276. doi:10.1097/01.CCM.0000127263.54807.79
Schulz KF, Altman DG, Moher D, CONSORT Group (2010) CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials. Ann Intern Med 152:726–732. doi:10.7326/0003-4819-152-11-201006010-00232
Wolkewitz M, Cooper BS, Bonten MJ, Barnett AG, Schumacher M (2014) Interpreting and comparing risks in the presence of competing events. BMJ 349:g5060. doi:10.1136/bmj.g5060
Young P, Saxena M, Bellomo R, Freebairn R, Hammond N, van Haren F, Holliday M, Henderson S, Mackle D, McArthur C, McGuinness S, Myburgh J, Weatherall M, Webb S, Beasley R, HEAT Investigators; Australian and New Zealand Intensive Care Society Clinical Trials Group (2015) Acetaminophen for fever in critically ill patients with suspected infection. N Engl J Med 373:2215–2224. doi:10.1056/NEJMoa1508375
Angrist JD, Imbens GW, Rubin DB (1996) Identification of causal effects using instrumental variables. J Am Stat Assoc 91:444–455
Kollef MH, Afessa B, Anzueto A, Veremakis C, Kerr KM, Margolis BD, Craven DE, Roberts PR, Arroliga AC, Hubmayr RD, Restrepo MI, Auger WR, Schinner R, NASCENT Investigation Group (2008) Silver-coated endotracheal tubes and incidence of ventilator-associated pneumonia: the NASCENT randomized trial. JAMA 300:805–813. doi:10.1001/jama.300.7.805
Rello J, Ollendorf DA, Oster G, Vera-Llonch M, Bellm L, Redman R, Kollef M (2002) Epidemiology and outcomes of ventilator-associated pneumonia in a large US database. Chest 122:2115–2121. doi:10.1378/chest.122.6.2115
Cook DJ, Walter SD, Cook RJ, Griffith LE, Guyatt GH, Leasa D, Jaeschke RZ, Brun-Buisson C (1998) Incidence of and risk factors for ventilator-associated pneumonia in critically ill patients. Ann Intern Med 129:433–440. doi:10.7326/0003-4819-129-6-199809150-00002
Marini JJ, Gattinoni L (2008) Propagation prevention: a complementary mechanism for “lung protective” ventilation in acute respiratory distress syndrome. Crit Care Med 36:3252–3258. doi:10.1097/CCM.0b013e31818f0e68
Simonis G, Flemming K, Ziegs E, Haacke K, Rauwolf T, Strasser RH (2007) Kinetic therapy reduces complications and shortens hospital stay in patients with cardiogenic shock - a retrospective analysis. Eur J Cardiovasc Nurs 6:40–45. doi:10.1016/j.ejcnurse.2006.03.008
Goldhill DR, Badacsonyi A, Goldhill AA, Waldmann C (2008) A prospective observational study of ICU patient position and frequency of turning. Anaesthesia 63:509–515. doi:10.1111/j.1365-2044.2007.05431.x
Ayzac L, Girard R, Baboi L, Beuret P, Rabilloud M, Richard JC, Guérin C (2015) Ventilator-associated pneumonia in ARDS patients: the impact of prone positioning. A secondary analysis of the PROSEVA trial. Intensive Care Med 42:871–878. doi:10.1007/s00134-015-4167-5
Hernán MA, Hernández-Díaz S (2012) Beyond the intention-to-treat in comparative effectiveness research. Clin Trials 9:48–55. doi:10.1177/1740774511420743
We deeply thank the nurses and respiratory therapists of all collaborating centers; this work would have been impossible without their help. Additionally, we acknowledge Alessandro Protti and Giacomo Grasselli for their support in implementing the study protocol.
Conflicts of interest
Mauro Panigada obtained research funds from the European Society of Intensive Care Medicine and Hill-Rom, Inc., Batesville, IN, USA, a manufacturer of hospital beds. All remaining authors declare no conflict of interest related to this manuscript. The project is endorsed by the ECCRN of the European Society of Intensive Care Medicine.
About this article
Cite this article
Li Bassi, G., Panigada, M., Ranzani, O.T. et al. Randomized, multicenter trial of lateral Trendelenburg versus semirecumbent body position for the prevention of ventilator-associated pneumonia. Intensive Care Med 43, 1572–1584 (2017). https://doi.org/10.1007/s00134-017-4858-1